Stocktoria
IRADIMED CORP IRMD
IRADIMED CORP (IRMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.25% (safety: stretched). FY2025 revenue was $83.8M at a 26.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.56 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.653 |
| Retained earnings / assets | 0.59 |
| EBIT / assets | 0.24 |
| Equity / liabilities | 6.683 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IRMD | IRADIMED CORP | 5/9 | 14.84 | 53.4 | +14.4% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| TELA | TELA Bio, Inc. | 3/9 | -13.97 | — | +15.8% |
| SGHT | Sight Sciences, Inc. | 5/9 | -5.95 | — | -3.1% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| RCEL | AVITA Medical, Inc. | 3/9 | — | — | +11.5% |
About IRADIMED CORP
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
FAQ
Is IRMD financially healthy?
IRADIMED CORP's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does IRMD pay a dividend, and is it safe?
Yes. IRADIMED CORP pays a dividend yielding about 1.25% with a 66.9% payout ratio, rated “stretched” for safety.
How profitable is IRMD?
In FY2025, IRADIMED CORP had a net margin of 26.8% and a return on equity of 23.8%.
Is IRMD overvalued or undervalued?
IRADIMED CORP trades at about 49.9× trailing earnings — near its 10-year norm (10-year range 15.2×–371.3×, median 52.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IRMD?
The average Wall-Street price target for IRADIMED CORP is $118.00, about 35.0% above the recent price, from 2 analysts.
Is IRMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IRADIMED CORP: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 53.4×, a dividend yield of 1.25%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.